无载体降解响应自组装的帕克利塔塞尔二元纳米药物与塞拉斯特醇协同作用,用于增强化疗免疫疗法
Yudi Lu1, Mei Zhou1, Xunfa Zhang1
1College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Asian journal of pharmaceutical sciences
|March 11, 2026
概括
这项研究引入了结合化疗 (帕克利塔塞尔) 和免疫疗法 (塞拉斯特罗尔) 的新型纳米颗粒,通过减少免疫抑制和改善药物输送来增强癌症治疗. 这种化疗免疫治疗方法显示出显著的抗瘤效果,具有良好的安全性.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 免疫治疗是一种免疫疗法.
背景情况:
- 帕克利塔塞尔 (PTX) 化疗可以通过PD-L1上调调节引起免疫抑制.
- 开发有效的组合疗法对于克服癌症治疗的局限性至关重要.
研究的目的:
- 设计和评估用于联合化疗免疫治疗的新型自组装纳米药物.
- 调查PTX和塞拉斯特 (Cel) 装载纳米粒子在向瘤和调节免疫微环境方面的有效性.
主要方法:
- 设计了无载体,降解敏感的PTX二极管自组装纳米制剂 (diPC NPs).
- diPC NPs包含一种对谷氨 (GSH) 敏感的PTX二元体前药物 (diPTX) 和醇 (Cel).
- 在体内研究在易斯肺癌和B16F10瘤携带的小鼠中进行.
主要成果:
- diPC NPs通过EPR效应显示出延长的循环和瘤积累.
- 瘤细胞中的GSH触发了PTX和Cel的快速释放,诱导免疫细胞死亡 (ICD).
- 细胞下调PD-L1表达,增强ICD和协同抗瘤功效.
结论:
- 开发的diPCNP为有效的组合化疗免疫疗法提供了一个有前途的战略.
- 这种方法有效地克服了PTX诱导的免疫抑制,并增强了抗瘤活性.
- 这些发现支持这种新型纳米药物改善癌症治疗的潜力.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.6K
08:29Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
10.6K
相关概念视频
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
76
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
76
